Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 13Terminated 3Withdrawn 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Sarcoma 1NET 1Lymphoid 1Gastrointestinal 1

Conditions

Prolactin-Producing Pituitary Tumor 1Lymphoma, Follicular 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

lutetium Lu 177 dotatate 16Magnetic Resonance Spectroscopy 14gallium Ga 68 dotatate 9Specimen Handling 8Everolimus 8pembrolizumab 7cabozantinib 6Cisplatin 6fluorodopa F 18 5Etoposide 5trametinib 4surufatinib 4lanreotide 4dabrafenib 4cemiplimab 4X-Rays 4Temozolomide 4Nivolumab 4Lutetium-177 4Lutetium 4Fluorodeoxyglucose F18 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4olaparib 3lenvatinib 3copper dotatate CU-64 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Surveys and Questionnaires 3Somatostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × pasireotide × Endocrine × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT06295952 2026-03-04

A Study of Pasireotide in People With Prolactinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
10 enrolled
Endocrine

Prolactin-Producing Pituitary Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡